Ron Henriksen

Chairman

Ron Henriksen, chairman, has more than thirty-five years of executive and managerial experience. Mr. Henriksen retired as president of Indiana University's Advanced Research and Technology Institute in 2002 to create a venture capital partnership investing in life science companies, Twilight Venture Partners, LLC.   Previously, Mr. Henriksen served as president and chief executive officer of a California-based biotechnology company, which he successfully sold in 1995 and in managerial and executive positions in marketing and finance with Eli Lilly and Company. Currently he is president and CEO of EndGenitor Technologies, Inc., an adult stem cell company, as well as Chairman and CEO of Semafore Pharmaceuticals, Inc., a signal transduction company, working on new cancer therapeutics.  Both of these companies are located in Indianapolis, IN. Mr. Henriksen holds a B.S. degree in industrial administration from Iowa State University and an M.B.A. "with distinction" from Harvard Business School.